CRISPR Therapeutics (NASDAQ:CRSP) Price Target Lowered to $82.00 at Chardan Capital
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price decreased by Chardan Capital from $84.00 to $82.00 in a research report sent to investors on Wednesday,Benzinga reports. Chardan Capital currently has a buy rating on the stock. Chardan Capital also issued estimates for CRISPR Therapeutics’ FY2026 earnings at ($3.97) EPS. A number of other […]
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price decreased by Chardan Capital from $84.00 to $82.00 in a research report sent to investors on Wednesday,Benzinga reports. Chardan Capital currently has a buy rating on the stock. Chardan Capital also issued estimates for CRISPR Therapeutics’ FY2026 earnings at ($3.97) EPS. A number of other […]
